GL · Globe Life Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average annual effective yield | 6.3% | Q2 2026 | — |
|
|
|||
| Average annual effective yield on Fixed Maturity Acquisitions | 6.3% | Quarter Ended June 30, 2026 | — |
| Book value per share excluding AOCI non-GAAP | $100.04 | June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Book value per share $78.18
+$21.86 Impact of adjustment to exclude AOCI
= Book value per share, excluding AOCI $100.04
|
|||
| Excess investment income non-GAAP | 38.32M | Three Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net investment income 293.82M
-255.51M Required interest on policy liabilities
= Excess investment income 38.32M
|
|||
| Excess investment income per share non-GAAP | $0.49 | Three Months Ended June 30, 2026 | — |
| Fixed Maturity Acquisitions amount | 399.14M | Quarter Ended June 30, 2026 | — |
| Health Net Sales | 70.4M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Insurance underwriting income non-GAAP | 370.29M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Life Net Sales | 149.61M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Net income as an ROE | 18.4% | Six Months Ended June 30, 2026 | — |
| Net operating income non-GAAP | 284.69M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Quarterly Average Producing Agent Count at American Income | 11,391 | Quarter Ended June 30, 2026 | — |
| Quarterly Average Producing Agent Count at Family Heritage | 1,608 | Quarter Ended June 30, 2026 | — |
| Quarterly Average Producing Agent Count at Liberty National | 4,194 | Quarter Ended June 30, 2026 | — |
| Shares of Globe Life Inc. common stock repurchased | 1.1M | Three Months Ended June 30, 2026 | — |
| Average producing agent count | 11,064 | Quarter Ended March 31, 2026 | — |
| Net operating income as an ROE excluding accumulated other comprehensive income (AOCI) non-GAAP | 14% | three months ended March 31, 2026 | — |
| Average producing agent count growth | 6% | Q4 2025 | — |
| Health net sales growth | 15% | Q4 2025 | — |
| Life net sales growth | 10% | Q4 2025 | — |
| Net health sales growth | 71% | Q4 2025 | — |
| Net sales of life insurance growth | 11% | Q4 2025 | — |
| Shares repurchased | 1.3M | Q4 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance - Life — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GL
this stock
Globe Life Inc.
|
$13.15B | +22.3% | +3.7% | 11.4 | 2.1% |
|
CILJF
China Life Insurance Co Ltd
|
$99.49B | +6.1% | — | — | 0.0% |
|
MFC
Manulife Financial Corp
|
$70.82B | +17.2% | — | — | 0.8% |
|
MET
Metlife Inc
|
$60.93B | +19.5% | +8.6% | 18.3 | 1.8% |
|
AFL
Aflac Inc
|
$58.19B | +5.3% | -9.3% | 12.5 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GL | -5.5% | -1.4% | +16.9% | -6.1% | +22.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -4.1% | -5.0% | +5.4% | -8.6% | +10.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.